

The Association between Vascular Endothelial Growth Factor-related Factors and Severity of Multiple Sclerosis

Ebrahim Kouchaki¹, Bentolhoda Otroshi Shahreza², Saiedeh Faraji²,
Hassan Nikouejad³, and Mojtaba Sehat⁴

¹ Department of Neurology, Kashan University of Medical Sciences, Kashan, Iran

² Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran

³ Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

⁴ Department of Community Medicine, Kashan University of Medical Sciences, Kashan, Iran

Received: 1 November 2015; Received in revised form: 4 February 2016; Accepted: 21 February 2016

ABSTRACT

Previous studies have demonstrated that vascular endothelial growth factor (VEGF) can trigger angiogenesis as well as inflammation through binding to its membranous receptor-1 on endothelial and inflammatory cells. We aimed to correlate the circulatory number of cells expressing such receptor as well as the serum level of VEGF and the soluble form of its receptor-1 (sVEGFR1) to the severity of multiple sclerosis (MS).

This case-control study was done on 102 cases of MS lacking any other inflammatory or pathologic conditions and 75 healthy volunteer subjects. The severity of MS was examined by expanded disability status scale (EDSS). The serum levels of VEGF and sVEGFR1 were measured by ELISA, and the circulatory frequency of VEGFR1 expressing cells was counted by flowcytometry. Then, the correlation of these variables was evaluated by Pearson's correlation coefficient and Spearman's test. We also investigated the influence of sex, age, treatment duration, and the number of recurrences on such association through linear multivariate regression method.

We found an increase in circulatory level of VEGFR1 expressing cells and the serum level of VEGF as well as sVEGFR1 in MS patients compared to healthy controls ($p < 0.001$). The greater severity of MS, the higher VEGFR1 expressing cells ($\rho = 0.47$; $p < 0.001$), serum level of VEGF ($\rho = 0.44$; $p < 0.001$), and sVEGFR1 ($\rho = 0.76$; $p < 0.001$). Having adjusted the effects of VEGF on sVEGFR1, we found a significant association between the EDSS score and sVEGFR1 ($\beta = 0.007$; $p < 0.001$).

Our findings revealed that circulatory membranous as well as soluble expression of VEGFR1 increases during angiogenic and inflammatory phenomena of MS. Such increase may exacerbate the symptoms and cause more disability.

Keywords: Multiple sclerosis; Soluble VEGFR1; Vascular endothelial growth factor receptor 1

Corresponding Author: Hassan Nikouejad, MD, PhD;
Nephrology and Urology Research Center, Baqiyatallah University of
Medical Sciences, Baqiyatallah Hospital, P.O.Box: 19395-5487,

Tehran, Iran; Tel: (+98 913) 1615 530, Fax: (+98 21) 8126 2073
E-mail: hnikuinejad@yahoo.com

INTRODUCTION

Multiple sclerosis (MS), as one of the most frequent neurologic diseases of young adults,¹ is a putative autoimmune disorder of the central nervous system (CNS). Clinically, it is characterized by recurrent episodes of neurologic dysfunction² resulting from lymphocytic infiltration to the CNS associated with activation of macrophages and microglia.³ The pathologic hallmarks of MS are multiple perivascular foci of myelin sheath destruction in a perivenular distribution of inflammatory cells as well as reactive astrogliosis.¹ The perivascular relationship of MS lesions is considered to be important for the pathogenesis of the disease,^{4,5} and in this regard, vascular endothelial growth factor (VEGF), as a heparin binding dimeric glycoprotein that induces the proliferation and migration of endothelial cells to form new vessels, increases the inflammation at least through penetration and extravasation of plasma macromolecules^{6,7} and immune cells such as monocyte/macrophages.⁸ Such roles may partly illustrate the pathologic role of VEGF in various inflammatory/autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and MS.⁹ In the case of MS, VEGF acts as both angiogenic factor which disrupts blood-brain barrier (BBB)¹⁰ and a chemotactic factor which in a VEGFR1 mediated pathway recruits circulatory monocytes,³ therefore, it seems to have a significant role in MS-related immune reactions.

VEGF exerts its biological effects by binding to its surface receptors including VEGF receptor-1 (VEGFR1, also known as Flt-1) and VEGFR2 (also known as kinase domain receptor (KDR) or Flk-1) both belonging to the class III receptor-type tyrosine kinase (RTK) receptor family.¹¹ VEGFR1 affinity to VEGF is 7–10 times higher than VEGFR2,¹²⁻¹⁵ and in this regard the chemotactic effects of VEGF are thought to be mediated through this receptor.⁵ VEGFR1 mediated signaling in endothelial and non-endothelial immune/nonimmune cells is responsible for both regulating angiogenesis¹⁶ and promoting VEGFR1 related pathologies such as cancer¹⁷ and rheumatoid arthritis.⁸

To reveal the association of such factors in MS, previous studies demonstrated some evidences such as elevated serum VEGF level attributable to spinal plaque length,⁹ overexpression of VEGF in MS and

EAE plaques¹⁸, and up regulation of VEGFR1 in samples of normal appearing white matter from post-mortem MS brains.¹⁹ Also, it has been shown that in MS plaques, macrophages outnumber T cells several folds and demyelination occurs in the proximity of macrophages rather than T cells.²⁰ On the other hand, there are some studies demonstrating decreased expression of VEGF level in MS plaques.²¹ However, literature lacks the frequency of VEGFR1 expressing cells in MS through which - if their increased circulatory level be proved - we would have an extra antagonising treatment option. Moreover, having assessed the correlation of VEGF-related factors with disease severity, we would have an accessible diagnostic tool - blood sampling versus CNS sampling - as a laboratory criterion of disability in practice.

In order to further clarify the role of VEGF and the potential therapeutic role of its surface and soluble receptors, we measured the serum level of VEGF as well as its soluble receptor-1 namely sVEGFR1, and circulatory frequency of cells expressing VEGFR1 in a group of MS patients and assessed their relationship to the severity of the disease.

MATERIALS AND METHODS

Study Subjects

Peripheral blood samples were simultaneously obtained from a total of 102 MS patients in remission phase being diagnosed according to clinical examination as well as MRI, and from 75 healthy controls being randomly selected from local blood donation organization in 2014. None of the patients suffered from any other autoimmune or inflammatory states; and no one took any immunomodulatory drugs. The Expanded Disability Status Scale (EDSS), the type of MS (CIS, RRMS, PPMS, SPMS, and PRMS), disease duration, treatment kind of the illness, and the number of recurrences were determined for each patient. Blood samples of all subjects were taken after signing the informed consent form approved by the local Ethical Committee. The study protocol conformed to the ethical guidelines of the 1975 Helsinki Declaration.

Flow Cytometric Analysis and ELISA

At least one million fresh peripheral blood mononuclear cells (PBMCs) were separated from 2 ml of anticoagulated blood by Ficoll-Hypaque

VEGF-related Factors and Severity of MS

(Lymphodex, Inno-Train, Germany) density gradient centrifugation. VEGFR1 expressing cells were detected by staining with an anti-human surface VEGFR1-PE antibody (R&D Systems) for 1 hour at room temperature in the dark. 2×10^6 mononuclear cells in each sample were gated on the basis of light and side scattering properties and then at least 20,000 events were obtained to count anti VEGFR1-PE-stained target cells. PE-labeled IgG1 isotype-matched control antibody was used to determine nonspecific binding. The percentages of such cells were analyzed by a 3-color flow-cytometry using BD FACScalibur Flow Cytometer and CELL Quest software version 3 (BD, USA). Serum levels of VEGF as well as sVEGFR1 were measured with commercial, sandwich type ELISA kits (eBioscience, USA) according to its instructions. Briefly, having prepared standard, blank, and sample wells, we orderly added 100 μ l Biotin conjugate, diluted streptavidin-HRP, TMB substrate solution, and stop solution, among each of which we incubated all wells. After blanking microwell reader, we measured the colour intensity at 450 nm. The limit of detection of such VEGF and sVEGFR1 kits has been determined to be 7.9 pg/ml and 0.03 ng/ml, respectively.

Statistical Analysis

Data were expressed as mean \pm SD. The statistical indices of VEGFR1 expressing cells and serum levels of VEGF as well as sVEGFR1 were analyzed using independent *t* and chi-square tests. Correlations between variables were calculated by Pearson's correlation coefficient and Spearman's test; and simultaneous effects of various factors on target cells were analyzed by linear multivariate regression method. EDSS score was normalized by logarithmic transformation. Adjusted R Squares were determined as a criterion of goodness-of-fit and they compared by Lr test. *p* values <0.05 were considered statistically significant. All analyses were performed using the STATA 10 and SPSS version 17 software.

RESULTS

Patients Characteristics and the Frequencies of the VEGFR1 Expressing Cells, Serum Levels of VEGF and sVEGFR1

Basic and clinical characteristics of both groups are shown in Table 1. Distribution of the frequency of VEGFR1 expressing cells and serum levels of VEGF as

well as sVEGFR1 in both groups were normal. The least EDSS score was seen in the most benign type of MS namely CIS, and then it was increasing in more severe types of MS. The frequency of circulatory VEGFR1 expressing cells and the serum level of VEGF as well as sVEGFR1 in MS patients were significantly higher than those in healthy controls ($p < 0.001$) (Table 1).

Association of the MS Severity with VEGF-related Factors

The frequency of circulatory VEGFR1 expressing cells and serum levels of VEGF as well as sVEGFR1 were different in MS patients according to EDSS score in such a way that they were significantly higher in severe forms of MS (EDSS=5-9.5) than those in mild forms (EDSS=0-4.5) ($p < 0.04$) (Table 2).

Correlation of the Serum Levels of VEGF with sVEGFR1 and the Frequency of VEGFR1 Expressing Cells

There was a significant correlation between VEGF with sVEGFR1 ($r=0.628$, $p < 0.001$) and the frequency of VEGFR1 expressing cells ($r=0.383$, $p < 0.001$) (Table 3). Considering all variables of age, EDSS scores, number of recurrences, and disease duration in adjusted model, we found each unit increase in VEGF raised the serum level of sVEGFR1 as 0.23 units ($p < 0.001$) ($R^2=0.61$) and the frequency of VEGFR1 expressing cells as 0.003 units ($p < 0.001$) ($R^2=0.18$) (data not shown).

Association of the Serum Levels of VEGF, sVEGFR1 and the Frequency of VEGFR1 Expressing Cells with Severity of MS

All factors of VEGF, sVEGFR1, and the frequency of VEGFR1 expressing cells showed significant associations with EDSS score. Modeling such association separately, we showed that, among all predictor variables, only the variables of age and the number of recurrences remained in the final model (Table 4). However, according to Lr test, the sVEGFR1 seems to be a better predictor of EDSS than the VEGF and the frequency of VEGFR1 expressing cells. Predictor model could be shown as:

$$\text{EDSS} = -1.2 + \text{age} \times 0.04 + \text{number of recurrences} \times 0.13 + \text{sVEGFR1} \times 0.007$$

Moreover, the correlation of the EDSS with sVEGFR1 ($p=0.76$) was more than that with VEGF ($p=0.44$) and frequency of VEGFR1 expressing cells ($p=0.47$).

Table 1. Demographic and clinical characteristics of MS patients and controls

		MS patients	Healthy controls	p value
Number of subjects		102	75	-
Male/female		16/86	19/56	0.08*
Age (years) mean±SD		32.3±11.47	31.4±10.65	0.07**
Family history (%)	Positive	13	-	-
	Negative	89	-	-
Disease duration (years) mean±SD		5.35±4.42	-	-
Treatment duration (years) mean±SD		2.75±3.16	-	-
Number of recurrences mean±SD		3.43±3.79	-	-
Number of patients in different types of MS	CIS	9	-	-
	RRMS	83	-	-
	PPMS	1	-	-
	SPMS	7	-	-
	PRMS	2	-	-
Number of patients using different kinds of drugs	Cinovex	82	-	-
	Rebief	11	-	-
	Betaferon	2	-	-
	Others	2	-	-
	No drug	5	-	-
EDSS (mean±SD)	CIS	1±1.06	-	-
	RRMS	2.1±1.5	-	-
	PPMS	6	-	-
	SPMS	4.9±1.43	-	-
	PRMS	6.03±0.35	-	-
VEGFR1 expressing cells±SD		3.41±1.69	1.85±0.99	<0.001**
Serum level of VEGF±SD		590.01±245.18	369.76±186.07	<0.001**
Serum level of sVEGFR1±SD		229.18±131.96	104.30±42.92	<0.001**

* Chi-square test

**independent t-test

Table 2. The frequency of circulatory VEGFR1 expressing cells and the serum levels of VEGF as well as sVEGFR1 according to different variables in MS patients

		VEGFR1 expressing cells ±SD	VEGF±SD	sVEGFR1±SD
EDSS	Mild (0-4.5)	3.28±1.65	561.76±232.94	210.36±120.69
	Sever (5-9.5)	4.29±1.71	779.05±250.19	355.20±139.64
	p value*	0.04	0.002	<0.001
Type	Mild (CIS, RRMS)	3.34±1.68	561.84±232.82	210.35±116.40
	Sever (PPMS, SPMS, PRMS)	3.94±1.7	803.79±241.56	338.60±150.42
	p value*	0.295	0.003	0.002
Sex	Male	3.28±1.58	646.08±237.65	265.35±155.08
	Female	3.43±1.71	579.33±246.52	222.30±126.99
	p value*	0.735	0.321	0.234
Family history	Positive	3.34±1.81	537.45±260.64	222.87±113.32
	Negative	3.42±1.68	597.86±243.40	230.13±135.08
	p value*	0.877	0.410	0.854

*independent t-test

VEGF-related Factors and Severity of MS

Table 3. Correlation between serum levels of sVEGFR1 as well as the frequency of VEGFR1 expressing cells with different variables in MS patients

	sVEGFR1		VEGFR1 expressing cells	
	Correlation coefficient	p value	Correlation coefficient	p value
VEGF	0.628	<0.001*	0.383	<0.001*
Age	0.268	0.008*	0.034	0.735*
EDSS	0.756	<0.001**	0.471	<0.001**
Number of recurrences	0.396	<0.001**	0.117	0.240**
Disease duration	0.382	<0.001**	0.114	0.257**
Treatment duration	0.217	0.031**	0.071	0.481**

*Pearson's correlation test

**Spearman's rho test

Table 4. Separate linear multiple regression analysis evaluating the effect of VEGF, sVEGFR1, and the frequency of VEGFR1 expressing cells with the severity of MS

Variables	Coefficients			t	Sig. p values	Adjusted R Squared
	B	Std. error	standardized B			
VEGF	0.002	0.001	0.317	4.18	<0.001	0.49
Number of recurrences	0.179	0.036	0.381	5.01	<0.001	
Age	0.054	0.012	0.344	4.55	<0.001	
sVEGFR1	0.007	0.001	0.513	7.31	<0.001	0.61
Number of recurrences	0.130	0.032	0.277	4.04	<0.001	
Age	0.043	0.010	0.272	4.06	<0.001	
Frequency of VEGFR1 expressing cells	0.287	0.083	0.273	3.48	0.001	0.46
Age	0.052	0.012	0.337	4.37	<0.001	
Number of recurrences	0.177	0.037	0.378	4.85	<0.001	

DISCUSSION

VEGF has been shown to be a very potent stimulator of angiogenesis and also a pro-inflammatory marker implicated in the pathology of a myriad of diseases including autoimmune neurological inflammatory diseases^{9,21-23} as well as tumours.^{24,25} Having considered the angiogenic effects of VEGF, some investigators have reported new findings centring on vascular pathology as a determining factor in the immuno-pathogenesis of MS.²⁶ One simple explanation of this concept is that new blood vessels facilitate immune cell migration and increase their adhesion as well as cytokine production.²⁷ Breakdown of the BBB is also a significant event in MS lesions; and mechanistically, the capability of VEGF to down regulate claudin-5 and occludins, key components of tight junctions, promotes BBB breakdown in murine MOG-EAE.¹⁰

Mediating VEGF effects on the cellular level, VEGF receptors contributes to its inflammatory consequences especially via the transcription factor "nuclear factor of activated T-cells" (NFAT).^{28,29} Not surprisingly, alterations in the VEGF/VEGFR system are observed in various inflammatory autoimmune diseases such as lupus erythematosus, inflammatory bowel disease, psoriasis, rheumatoid arthritis and MS.² Understandably, yielding any pathology, such alterations in the amount of VEGF would negatively or positively be regulated by VEGFR. This might explain the reason of that increased level of VEGF in human rheumatoid arthritis³⁰⁻³² and also its correlation with the disease severity³³⁻³⁵ that could be therapeutically inverted via a soluble form of the VEGFR1 (sFlt1) (which traps VEGF) in murine collagen-induced arthritis (CIA).³⁶ A recombinant version of natural sVEGFR1^{37,38} as well as its adenovirus- or plasmid-mediated gene transfer³⁹ was shown to inhibit

angiogenesis and inflammatory indices. In line with these concepts, antagonizing VEGF signalling has been effective in animal models of psoriasis,⁴⁰⁻⁴¹ rheumatoid arthritis³⁶ and MS.²³ Notably, antagonizing VEGFR-2, the main VEGF receptor, ameliorates murine acute MOG-EAE²³ which is well in line with a predominant anti-inflammatory mode of action of this treatment.

There are some varieties regarding VEGF and its related factors in MS. While VEGF serum levels have been reported to elevate during both remission and relapse phases,⁹ VEGFR1 expression may decrease in chronic active MS lesions compared to normal white matter.⁴² Also, examining CNS samples, the investigators have demonstrated that VEGF/VEGFR2 expression may consistently be up-regulated in both acute and chronic MS plaques (paralleled by an increased amount of microvessels) and also during the course of EAE in association with inflammatory cells.¹⁸ Conversely, one study reported the down-regulation of VEGF in CSF mononuclear cells from MS patients and also astroglia of Lewis rats suffering from EAE.²¹ The surprisingly multiple effects of VEGF in CNS has been reconciled, considering that VEGF splice variants could result in opposite effects due either to binding with different affinity VEGF-Rs and Neuropilin-1 or to differential tyrosine residue phosphorylation of VEGFRs.⁴³

Our results showed higher circulatory number of VEGFR1 bearing cells and the serum levels of VEGF as well as sVEGFR1 in a great number of MS patients than those in the control group. This may indicate potential pathogenic effect of VEGF and its related factors in MS. Furthermore, our data reveals that the higher numbers of such cells as well as such serum levels were associated with severity of the disease. This means that the effects of disease severity may act mainly via VEGF and VEGFR1 expression.

Showing a significant positive correlation between the VEGF and sVEGFR1 in our patients, we may consider that following VEGF increase in more severe types of MS, sVEGFR1 increases likely as a protective mechanism ameliorating the disease pathology. This concept may confirm the beneficial effect of sVEGFR1 which has recently been concerned as a novel therapy in autoimmune diseases like MS.⁴⁴ However, finding a strong correlation between EDSS and sVEGFR1 after adjusting the effects of VEGF, we showed that sVEGFR1 increases in severe forms of MS independently to VEGF.

Although we showed a significant association between the frequency of VEGFR1 expressing cells as well as VEGF with severity of MS, we found that sVEGFR1 may be a stronger predictor of MS severity in the presence of factors including age, sex, number of recurrences, and disease duration. Maybe other factors except the evaluated ones in our study may affect the MS severity which should be defined in other studies.

Studying the probable changes of VEGF-related factors in the underlying chronic inflammation of MS, we considered a homogenous population of the patients in remission phase. Obviously, such homogeneity renders more reliable findings in the absence of confounding factor of exacerbations. Our assessment also yields a simple practical application of such factors as clues of underlying severity for prognostic and at the same time therapeutic suggestions in an outpatient management. Actually, we recommend an easier as well as cheaper way to be taken in practice rather than CSF sampling as well as MRI which have already been done.

The limitation of our study was, firstly, lack of monitoring circulatory changes of VEGFR1 expressing cells and serum levels of VEGF as well as sVEGFR1 longitudinally. This limitation allowed just a cross-sectional analysis of such cell profiles of only limited robustness. Secondly, functional assays which provide further information on the immune status of the disease according to the serum levels as well as the number of such parameters were not performed.

Our findings reveal that VEGFR1 expressing cells and serum levels of VEGF/sVEGFR1 increase in MS patients as some angiogenic as well as inflammatory factors. Such increase was associated with MS severity; therefore, it may show exacerbating the symptoms and more disability. Considering such issue, we may use VEGF/VEGFR1 blockers as well as recombinant forms of sVEGFR1 to decrease the angiogenesis as a key method for treatment and decreasing the symptom and disability of MS.

ACKNOWLEDGEMENTS

This study funded and supported by Deputy of Research, Kashan University of Medical Sciences (kaums), and Grant No. 92101.

The authors have no conflicts of interest to declare.

VEGF-related Factors and Severity of MS

REFERENCES

1. Adams RD, Victor M, Ropper A. Multiple sclerosis and allied demyelinating diseases. Principles of Neurology New York: McGraw-Hill 1997; 902-27.
2. Carvalho JIF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. *J Clin Immunol* 2007; 27(3):246-56.
3. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. *Blood* 1996; 87(8):3336-43.
4. Poser CM. The role of trauma in the pathogenesis of multiple sclerosis: a review. *Clin Neurol Neurosurg* 1994; 96(2):103-10.
5. Gay D, Esiri M. Blood brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. *Brain* 1991; 114(1):557-72.
6. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. *Am J Pathol* 1995; 146(5):1029-39.
7. Conn G, Soderman DD, Schaeffer M-T, Wile M, Hatcher VB, Thomas KA. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. *Proc Natl Acad Sci U S A* 1990; 87(4):1323-7.
8. Claudio L, Kress Y, Norton WT, Brosnan C. Increased vesicular transport and decreased mitochondrial content in blood-brain barrier endothelial cells during experimental autoimmune encephalomyelitis. *Am J Pathol* 1989; 135(6):1157-68.
9. Su JJ, Osoegawa M, Matsuoka T, Minozono M, Tanaka M, Ishizu T, et al. Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. *J Neurol Sci* 2006; 243(1-2):21-30.
10. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. *Proc Natl Acad Sci U S A* 2009; 106(6):1977-82.
11. Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. *Neuron* 1992; 9(3):383-91.
12. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. *Biochem Biophys Res Commun* 1996; 226(2):324-8.
13. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. *Cell Growth Differ* 1996; 7(2):213-21.
14. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. *Science* 1992; 255(5047):989-91.
15. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. *Biochem Biophys Res Commun* 1992; 187(3):1579-86.
16. Cao R, Xue Y, Hedlund E-M, Zhong Z, Tritsarlis K, Tondelli B, et al. VEGFR1-mediated pericyte ablation links VEGF and PIGF to cancer-associated retinopathy. *Proc Natl Acad Sci U S A* 2010; 107(2):856-61.
17. Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y. Vascular endothelial growth factor receptor-1 in human cancer. *Cancer* 2010; 116(4 Suppl):1027-32.
18. Proescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merrill MJ. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. *J Neuropathol Exp Neurol* 2002; 61(10):914-25.
19. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. *Brain Pathol* 2003; 13(4):554-73.
20. Williams K, Ulvestad E, Hickey W. Immunology of multiple sclerosis. *Clin Neurosci* 1993; 2(3-4):229-45.
21. Tham E, Gielen A, Khademi M, Martin C, Piehl F. Decreased Expression of VEGF-A in Rat Experimental Autoimmune Encephalomyelitis and in Cerebrospinal Fluid Mononuclear Cells from Patients with Multiple Sclerosis. *Scand J Immunol* 2006; 64(6):609-22.
22. Kirk S, Karlik S. VEGF and vascular changes in chronic neuroinflammation. *J Autoimmun* 2003; 21(4):353-63.
23. Roscoe W, Welsh M, Carter D, Karlik S. VEGF and angiogenesis in acute and chronic MOG (35-55) peptide induced EAE. *J Neuroimmunol* 2009; 209(1-2):6-15.
24. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. *Nat Med* 2003; 9(6):669-76.
25. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. *Proc Natl Acad Sci U S A* 1998; 95(15):8795-800.
26. Waschbisch A, Manzel A, Linker RA, Lee D-H. Vascular

- pathology in multiple sclerosis: mind boosting or myth busting? *Exp Transl Stroke Med* 2011; 3(1):7.
27. Jackson JR, Seed M, Kircher C, Willoughby D, Winkler J. The codependence of angiogenesis and chronic inflammation. *FASEB J* 1997;11(6):457-65.
 28. Schweighofer B, Testori J, Sturtzel C, Sattler S, Mayer H, Wagner O, et al. The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. *Thromb Haemost* 2009; 102(3):544-54.
 29. Fukushima K, Miyamoto S, Tsukimori K, Kobayashi H, Seki H, Takeda S, et al. Tumor necrosis factor and vascular endothelial growth factor induce endothelial integrin repertoires, regulating endovascular differentiation and apoptosis in a human extravillous trophoblast cell line. *Biol Reprod* 2005; 73(1):172-9.
 30. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1995; 1(1):27-30.
 31. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? *Arthritis Rheum* 1996; 39(11):1781-90.
 32. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. *J Immunol* 1994; 152(8):4149-56.
 33. Ballara S, Taylor PC, Reusch P, Marm' D, Feldmann M, Maini RN, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. *Arthritis Rheum* 2001; 44(9):2055-64.
 34. De Bandt M, Grossin M, Weber AJ, Chopin M, Elbim C, Pla M, et al. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. *Arthritis Rheum* 2000; 43(9):2056-63.
 35. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. *Arthritis Rheum* 2002; 46(10):2587-97.
 36. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. *Lab Invest* 2000; 80(8):1195-205.
 37. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. *Cancer Res* 2000; 60(8):2169-77.
 38. Honda M, Sakamoto T, Ishibashi T, Inomata H, Ueno H. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. *Gene therapy* 2000; 7(11):978-85.
 39. Zhu C-S, Hu X-Q, Xiong Z-J, Lu Z-Q, Zhou G-Y, Wang D-J. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) inhibits experimental autoimmune encephalomyelitis in dark Agouti (DA) rats. *Life Sci* 2008; 83(11-12):404-12.
 40. Halin C, Fahrngruber H, Meingassner JG, Bold G, Littlewood-Evans A, Stuetz A, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. *Am J Pathol* 2008; 173(1):265-77.
 41. Schonhaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. *Proc Natl Acad Sci U S A* 2009; 106(50):21264-9.
 42. Seabrook TJ, Littlewood-Evans A, Brinkmann V, Pollinger B, Schnell C, Hiestand PC. Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions. *J Neuroinflammation* 2010;7(1):95.
 43. Girolamo F, Coppola C, Ribatti D, Trojano M. Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. *Acta Neuropathol Commun* 2014; 2:84.
 44. Zhu C, Xiong Z, Chen X, Lu Z, Zhou G, Wang D, et al. Soluble vascular endothelial growth factor (VEGF) receptor-1 inhibits migration of human monocytic THP-1 cells in response to VEGF. *Inflamm Res* 2011; 60(8):769-74.